Zhenghe Chen
Overview
Explore the profile of Zhenghe Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
80
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duan H, He Z, Chen Z, Chen Y, Hu W, Sai K, et al.
BMC Immunol
. 2024 Dec;
25(1):83.
PMID: 39707189
Purpose: Immunotherapy is a promising treatment for cancers but should be optimized for malignant gliomas. Because of immune privilege feature of the brain, local administration of immunotherapy may be a...
2.
Xiong M, Chen Z, Zhou C, Yang X, Hu W, Jiang Y, et al.
Recent Pat Anticancer Drug Discov
. 2024 Jan;
19(3):383-395.
PMID: 38214322
Background: Glioma is characterized by a high recurrence rate, while the results of the traditional imaging methods (including magnetic resonance imaging, MRI) to distinguish recurrence from treatment-related changes (TRCs) are...
3.
Zhu S, Cheng Z, Wu Z, Liang Q, Chen S, Zhang J, et al.
J Racial Ethn Health Disparities
. 2023 Aug;
11(4):1843-1856.
PMID: 37548855
Background: Medulloblastoma (MB) is the most common malignant brain tumor of childhood. The associations between socioeconomic statuses (SES) and survival outcomes of medulloblastoma remain unclear. The aim of this study...
4.
Guo C, Yang Q, Xu P, Deng M, Jiang T, Cai L, et al.
JAMA Netw Open
. 2023 Jan;
6(1):e2253285.
PMID: 36705923
Importance: High-grade gliomas (HGGs) constitute the most common and aggressive primary brain tumor, with 5-year survival rates of 30.9% for grade 3 gliomas and 6.6% for grade 4 gliomas. The...
5.
Wang F, Chen L, Wang Z, Xu Q, Huang H, Wang H, et al.
Cancer Cell Int
. 2022 Oct;
22(1):320.
PMID: 36242047
Background: Brain metastases (BM) from non-small-cell lung cancer (NSCLC) is the most common brain malignancy. Systemic inflammation biomarkers have recently been evaluated as prognosis indicators in several tumors. The combination...
6.
Zhu S, Cheng Z, Hu Y, Chen Z, Zhang J, Ke C, et al.
Front Nutr
. 2022 Jan;
8:754958.
PMID: 34977115
The progression and metastasis of cancers are associated with systematic immune inflammation and nutritional dysfunction. The systemic immune-inflammation index and prognostic nutritional index (PNI) have shown a prognostic impact in...
7.
Su C, Xu S, Lin D, He H, Chen Z, Damen F, et al.
Eur Radiol
. 2021 Jul;
32(1):101-111.
PMID: 34272981
Objectives: To comprehensively and noninvasively risk-stratify glioma grade, isocitrate dehydrogenase (IDH) genotype, and 1p/19q codeletion status using multi-contrast Z-spectral magnetic resonance imaging (MRI). Methods: One hundred and thirteen patients with...
8.
Lv X, Jiang Y, Wang X, Xie H, Dou G, Wang J, et al.
Med Oncol
. 2021 Jul;
38(8):94.
PMID: 34259934
Ideal lead compounds and candidate drugs with inhibitory effect on BCL2 were screened from ZINC database, which laid a foundation for drug development and compound improvement of drug treatment for...
9.
Zhong S, Wu B, Yang W, Ge J, Zhang X, Chen Z, et al.
Aging (Albany NY)
. 2021 Jan;
13(2):1898-1912.
PMID: 33486472
Object: This study was designed to screen ideal lead compounds and drug candidates with an inhibitory effect on PARP from the drug library (ZINC database). Results: Two effective natural compounds...
10.
Zhu S, Chen Y, Lin F, Chen Z, Jiang X, Zhang J, et al.
J Clin Neurosci
. 2021 Jan;
84:66-74.
PMID: 33485602
Decompressive craniectomy is widely used to treat medically refractory intracranial hypertension. There were still few studies focusing on the complications between titanium cranioplasty with non-titanium materials cranioplasty. Our systematic review...